Stockreport

BeyondSpring’s Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 Trial

BeyondSpring, Inc. - Ordinary Shares  (BYSI) 
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.beyondspringpharma.com
PDF Data Provide Further Support for Plinabulin’s Superior Product Profile Clinical Data Will be Presented at 2018 IASLC 19th World Conference on Lung Cancer NEW YORK , Se [Read more]